In Brief: Perkin-Elmer/Hyseq
This article was originally published in The Gray Sheet
Perkin-Elmer/Hyseq: Firms ink strategic partnership agreement to commercialize DNA microchip technology which includes a $10 mil. equity investment in Hyseq by Perkin-Elmer, P-E announces June 19. Under the terms of the deal, both firms will invest additional research funds in Hyseq's proprietary DNA HyChip technology. Combination of the HyChip technology with P-E DNA analysis technologies is anticipated to enable creation of a DNA chip "that can assay any genetic target through the use of specially designed reagents and software," P-E says. P-E will have exclusive worldwide rights to commercialize sequencing systems using the HyChip technology under the agreement...
You may also be interested in...
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.